The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for LGC sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
LGC Ltd (LGC) is a life sciences measurement and testing company that offers genomics solutions and quality assurance services. The company’s products portfolio comprises GMP and RUO oligonucleotides, molecular biology reagents, NGS kits and enzymes, oligo synthesis reagents and instruments, PCR reagents and instruments and sample prep reagents and instruments among others. It also provide oligonucleotide- & mRNA-based therapeutics to deliver best solutions for nucleic acid therapeutics’ development, ranging from lead ID, across all clinical stages, to commercial supply. The company serves healthcare, food, beverage and environmental, animal breeders, seed producers and aquaculture, research institutes and universities and the government sector. The company operates in Brazil, Bulgaria, Canada, China, Denmark, France, Germany, Hungary, India, Italy, the UK and the US, among others. LGC is headquartered in Teddington, Middlesex, the UK. Key subsidiaries of LGC include Rapid Genomics, Paragon Scientific, Native Antigen, Toronto Research Chemicals and Technopath Clinical Diagnostics.
The key metrics of LGC related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As LGC is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as LGC.
For a detailed understanding of the performance of LGC, buy the report here.